(P010) Stereotactic Body Radiotherapy for Treatment of Adrenal Gland Metastasis: Toxicity, Outcomes, and Patterns of Failure

Publication
Article
OncologyOncology Vol 29 No 4_Suppl_1
Volume 29
Issue 4_Suppl_1

SBRT is an effective treatment modality, achieving excellent local control with minimal toxicity for patients with adrenal metastases. The development of progressive distant metastasis is the predominant pattern of failure affecting patients’ survival outcomes.

William W. Chance, MD, Quynh-Nhu Nguyen, MD, Reza J. Mehran, MD, James W. Welsh, MD, Daniel R. Gomez, MD, Peter A. Balter, PhD, Ritsuko Komaki, MD, Zhongxing Liao, MD, Joe Y. Chang, MD, PhD; UT MD Anderson Cancer Center

PURPOSE: A single-institution, retrospective review of toxicity, patterns of failure, and outcomes in patients undergoing stereotactic body radiotherapy (SBRT) for metastasis to the adrenal gland.

MATERIALS AND METHODS: From 2009–2014, a total of 36 patients with 40 adrenal metastases were treated with SBRT. The median age of the patient population was 63.7 years (range: 50–77 yr). Primary sites included lung (n = 31), ovary (n = 2), bladder (n = 1), esophagus (n = 1), and melanoma (n = 1). A total of 32 patients received treatment to a single adrenal gland, while 4 patients received treatment to the bilateral adrenal glands. The prescription dose to the target was 60 Gy in 10 fractions (n = 25), 50 Gy in 10 fractions (n = 10), 50 Gy in 4 fractions (n = 4), or other (n = 4). Failures within the prescribed high-dose irradiated region were considered local failures. New or progressive distant metastases outside of the treated adrenal gland were considered distant failures. After review of the radiation treatment plan, local failures were characterized as in-field (epicenter within the 100% isodose line) or marginal (between the 50% and 100% isodose lines).

RESULTS: Median follow-up was 12.6 months after radiation treatment (range: 1.4–37.1 mo). Six patients developed grade 1 gastrointestinal toxicity. Two patients who were treated to the bilateral adrenal glands developed grade 2 adrenal insufficiency. There was no grade 3 or 4 toxicity observed. Median overall survival after treatment was 19.5 months. The 1- and 2-year overall survival rates were 67% and 55%, respectively. The 1-year freedom from local failure was 87%. The median time to local failure was not reached. The 1-year freedom from disease progression was 25% (median time to progression, 5.9 mo). The 1-year freedom from distant failure was 33% (median time to distant failure, 6.0 mo). There were six in-field local failures and one marginal failure observed.

CONCLUSION: SBRT is an effective treatment modality, achieving excellent local control with minimal toxicity for patients with adrenal metastases. The development of progressive distant metastasis is the predominant pattern of failure affecting patients’ survival outcomes.

Proceedings of the 97th Annual Meeting of the American Radium Society - americanradiumsociety.org

Articles in this issue

(P005) Ultrasensitive PSA Identifies Patients With Organ-Confined Prostate Cancer Requiring Postop Radiotherapy
(P001) Disparities in the Local Management of Breast Cancer in the United States According to Health Insurance Status
(P002) Predictors of CNS Disease in Metastatic Melanoma: Desmoplastic Subtype Associated With Higher Risk
(P003) Identification of Somatic Mutations Using Fine Needle Aspiration: Correlation With Clinical Outcomes in Patients With Locally Advanced Pancreatic Cancer
(P004) A Retrospective Study to Assess Disparities in the Utilization of Intensity-Modulated Radiotherapy (IMRT) and Proton Therapy (PT) in the Treatment of Prostate Cancer (PCa)
(S001) Tumor Control and Toxicity Outcomes for Head and Neck Cancer Patients Re-Treated With Intensity-Modulated Radiation Therapy (IMRT)-A Fifteen-Year Experience
(S003) Weekly IGRT Volumetric Response Analysis as a Predictive Tool for Locoregional Control in Head and Neck Cancer Radiotherapy 
(S004) Combination of Radiotherapy and Cetuximab for Aggressive, High-Risk Cutaneous Squamous Cell Cancer of the Head and Neck: A Propensity Score Analysis
(S005) Radiotherapy for Carcinoma of the Hypopharynx Over Five Decades: Experience at a Single Institution
(S002) Prognostic Value of Intraradiation Treatment FDG-PET Parameters in Locally Advanced Oropharyngeal Cancer
(P006) The Role of Sequential Imaging in Cervical Cancer Management
(P008) Pretreatment FDG Uptake of Nontarget Lung Tissue Correlates With Symptomatic Pneumonitis Following Stereotactic Ablative Radiotherapy (SABR)
(P009) Monte Carlo Dosimetry Evaluation of Lung Stereotactic Body Radiosurgery
(P010) Stereotactic Body Radiotherapy for Treatment of Adrenal Gland Metastasis: Toxicity, Outcomes, and Patterns of Failure
(P011) Stereotactic Radiosurgery and BRAF Inhibitor Therapy for Melanoma Brain Metastases Is Associated With Increased Risk for Radiation Necrosis
Related Videos
Considering cystectomy in patients with bladder cancer may help with managing the shortage of Bacillus Calmette-Guerin, according to Joshua J. Meeks, MD, PhD, BS.
Anemia in patients who receive talazoparib plus enzalutamide for metastatic castration-resistant prostate cancer appears to be manageable without any compromises in patient-reported outcomes and quality of life.
Patients with locally advanced or metastatic urothelial cancer and visceral disease may particularly benefit from enfortumab vedotin plus pembrolizumab, according to Amanda Nizam, MD.
High-grade adverse effects with zanidatamab plus palbociclib and fulvestrant seem to be uncommon in patients with HER2-positive, hormone receptor–positive, metastatic breast cancer, according to Sara Hurvitz, MD, FACP.
Black male patients with breast cancer appear to experience worse survival outcomes compared with White patients when controlling for clinicopathological variables, according to Jason (Jincong) Q. Freeman, MPH, MS.
Results from the ECOG-ACRIN E4112 trial appear to support the use of DCIS scores for identifying patients with breast cancer who may be eligible to omit radiotherapy following MRI-guided surgery.
Providers should inform patients with breast cancer that selecting later-line therapies following prior treatment with CDK4/6 inhibitors is a “developing area,” says Abigail M. Johnston, JD.
Data from the phase 3 NATALEE trial highlight a positive toxicity profile for ribociclib as an adjuvant therapy for patients with hormone receptor–positive, HER2-negative breast cancer, says Neil M. Iyengar, MD.
Future research will focus on ctDNA dynamics change over time in the full translational cohort of patients with hormone receptor–positive breast cancer in the phase 3 monarchE study, says Stephanie L. Graff, MD.
Findings from a National Cancer Database analysis highlight no statistically significant differences in survival outcomes with chemotherapy for patients over 81 years old with triple-negative breast cancer compared with those who do not receive chemotherapy.
Related Content